Kick off a new Innovative Medicine Initiative 2 (IMI2)-Project: 3TR

Kick off a new Innovative Medicine Initiative 2 (IMI2)-Project: 3TR
We are very pleased to announce that the DRFZ is partner of the largest-ever Innovative Medicine Initiative 2 (IMI2) immunology project to improve disease management of non-responders to therapy across seven immune-mediated diseases called Taxonomy, Treatment, Targets and Remission (3TR): Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions.

About 3TR
3TR brings together 69 partner organizations from 15 European member states including academic and research institutions, small and medium-sized enterprises (SME) and pharmaceutical companies. For a full partner list, please visit: www.3tr-imi.eu/partners

The project is supported with a funding of over € 80 million from the Innovative Medicines Initiative 2 (IMI2), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Visit the 3TR website: www.3tr-imi.eu
Follow 3TR on Twitter: @3TR_IMI

Role of DRFZ within 3TR
Within WP1 and WP4 of the 3TR project the DRFZ provides its expertise on high-throughput microbiota analysis by high-resolution microbiota cytometry, high-dimensional single cell analysis and immune monitoring as well as the knowledge of the etiopathology of chronic inflammation.

PIs at DRFZ
Hyun-Dong Chang
Falk Hiepe
Henrik Mei
Andreas Radbruch